South Carolina Research Studies Directory

A Phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Date Added
April 28th, 2026
PRO Number
Pro00148327
Researcher
Don Rockey

List of Studies


Keywords
Liver
Summary

To investigate the safety, tolerability, PD, and PK of BI 3802876
when administered intravenously in single rising doses following
MABEL dose administration in adult patients with compensated
cirrhosis due to MASH.

Institution
MUSC
Recruitment Contact
Bridgette Blankenship
8438768439
blanke@musc.edu

Case-Control Study of a Novel Test for the Early Detection of Hepatocellular Carcinoma in at-risk Patients with Cirrhosis

Date Added
May 1st, 2026
PRO Number
Pro00149583
Researcher
Don Rockey

List of Studies


Keywords
Cancer, Liver
Summary

This study will enroll patients that were either diagnosed with hepatocellular cancer (HCC) in the past 6 weeks or have been diagnosed with cirrhosis but do not have HCC. Patients will have a blood sample collected to test if a new blood-based biomarker is accurate in the early detectection of HCC.

Institution
MUSC
Recruitment Contact
Bridgette Blankenship
(843)-876-8439
blanke@musc.edu

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (ELASCOPE)

Date Added
July 23rd, 2026
PRO Number
Pro00150319
Researcher
Don Rockey

List of Studies


Keywords
Liver
Summary

To evaluate if daily oral administration of elafibranor 120 mg improves the time of event free survival compared to placebo in adults with Primary Sclerosing Cholangitis (PSC).

Institution
MUSC
Recruitment Contact
Joshua Inman
843-876-4303
inmanj@musc.edu



-- OR --